{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=efgartigimod", "query": { "intervention": "efgartigimod" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 51, "total_pages": 6, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=efgartigimod&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-02T07:36:19.338Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05633407", "title": "Efficacy and Safety Study of Efgartigimod in Adults With Post-COVID-19 POTS", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Postural Orthostatic Tachycardia Syndrome" ], "interventions": [ { "name": "Efgartigimod", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "argenx", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 53, "start_date": "2022-09-23", "completion_date": "2024-04-18", "has_results": true, "last_update_posted_date": "2025-05-23", "last_synced_at": "2026-09-02T07:36:19.338Z", "location_count": 11, "location_summary": "La Jolla, California • Palo Alto, California • Glenview, Illinois + 8 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Glenview", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05633407" }, { "nct_id": "NCT06503731", "title": "A Study to Evaluate the Safety and Tolerability of Efgartigimod PH20 SC Given by Prefilled Syringe in Kidney Transplant Recipients With Antibody-Mediated Rejection (AMR)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Antibody-mediated Rejection" ], "interventions": [ { "name": "Efgartigimod PH20 SC - prefilled syringe", "type": "COMBINATION_PRODUCT" }, { "name": "Placebo PH20 SC - prefilled syringe", "type": "OTHER" } ], "intervention_types": [ "COMBINATION_PRODUCT", "OTHER" ], "sponsor": "argenx", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 33, "start_date": "2024-08-30", "completion_date": "2027-11", "has_results": false, "last_update_posted_date": "2026-07-02", "last_synced_at": "2026-09-02T07:36:19.338Z", "location_count": 8, "location_summary": "Birmingham, Alabama • Los Angeles, California • Chicago, Illinois + 5 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Omaha", "state": "Nebraska" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT06503731" }, { "nct_id": "NCT04281472", "title": "A Study to Assess the Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)" ], "interventions": [ { "name": "efgartigimod PH20 SC in stage B", "type": "BIOLOGICAL" }, { "name": "placebo in stage B", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "argenx", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 322, "start_date": "2020-04-15", "completion_date": "2023-05-11", "has_results": true, "last_update_posted_date": "2024-08-20", "last_synced_at": "2026-09-02T07:36:19.338Z", "location_count": 45, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 38 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Carlsbad", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04281472" }, { "nct_id": "NCT06307626", "title": "A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease.", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Thyroid Eye Disease" ], "interventions": [ { "name": "Efgartigimod PH20 SC", "type": "COMBINATION_PRODUCT" }, { "name": "Placebo PH20 SC", "type": "OTHER" } ], "intervention_types": [ "COMBINATION_PRODUCT", "OTHER" ], "sponsor": "argenx", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 105, "start_date": "2024-03-28", "completion_date": "2026-02-12", "has_results": false, "last_update_posted_date": "2026-03-16", "last_synced_at": "2026-09-02T07:36:19.338Z", "location_count": 11, "location_summary": "Los Angeles, California • Mission Hills, California • Rancho Cordova, California + 8 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Mission Hills", "state": "California" }, { "city": "Rancho Cordova", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Boynton Beach", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06307626" }, { "nct_id": "NCT06307613", "title": "A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Thyroid Eye Disease" ], "interventions": [ { "name": "Efgartigimod PH20 SC", "type": "COMBINATION_PRODUCT" }, { "name": "Placebo PH20 SC", "type": "OTHER" } ], "intervention_types": [ "COMBINATION_PRODUCT", "OTHER" ], "sponsor": "argenx", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 102, "start_date": "2024-03-27", "completion_date": "2026-02-12", "has_results": false, "last_update_posted_date": "2026-03-16", "last_synced_at": "2026-09-02T07:36:19.338Z", "location_count": 16, "location_summary": "Beverly Hills, California • Irvine, California • Los Angeles, California + 13 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Coral Springs", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06307613" }, { "nct_id": "NCT05267600", "title": "A Phase 2/3 Study of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Bullous Pemphigoid" ], "interventions": [ { "name": "efgartigimod PH20 SC", "type": "BIOLOGICAL" }, { "name": "placebo", "type": "OTHER" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "OTHER", "DRUG" ], "sponsor": "argenx", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 98, "start_date": "2022-06-09", "completion_date": "2024-09-13", "has_results": true, "last_update_posted_date": "2025-10-23", "last_synced_at": "2026-09-02T07:36:19.338Z", "location_count": 21, "location_summary": "Phoenix, Arizona • Fountain Valley, California • Redwood City, California + 18 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Redwood City", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Castle Rock", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT05267600" }, { "nct_id": "NCT07284420", "title": "ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "AChR-Ab Seropositive Generalized Myasthenia Gravis", "Myasthenia Gravis", "MG", "gMG", "Generalized Myasthenia Gravis", "Generalized Myasthenia Gravis (gMG)" ], "interventions": [ { "name": "Efgartigimod IV", "type": "BIOLOGICAL" }, { "name": "Empasiprubart IV", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "argenx", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 70, "start_date": "2025-12-19", "completion_date": "2028-03-07", "has_results": false, "last_update_posted_date": "2026-08-21", "last_synced_at": "2026-09-02T07:36:19.338Z", "location_count": 11, "location_summary": "Carlsbad, California • Miami, Florida • Tampa, Florida + 8 more", "locations": [ { "city": "Carlsbad", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT07284420" }, { "nct_id": "NCT07264426", "title": "Real-World Efgartigimod Effectiveness in CIDP: A Prospective Study", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Chronic Inflammatory Demyelinating Polyradiculoneuropathy", "CIDP", "CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy)" ], "interventions": [ { "name": "Efgartigimod PH20 SC", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "argenx", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 200, "start_date": "2025-08-11", "completion_date": "2029-10", "has_results": false, "last_update_posted_date": "2026-04-23", "last_synced_at": "2026-09-02T07:36:19.338Z", "location_count": 1, "location_summary": "Wilmington, North Carolina", "locations": [ { "city": "Wilmington", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT07264426" }, { "nct_id": "NCT03669588", "title": "An Efficacy and Safety Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Generalized Myasthenia Gravis" ], "interventions": [ { "name": "ARGX-113", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "argenx", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 167, "start_date": "2018-08-22", "completion_date": "2020-04-06", "has_results": true, "last_update_posted_date": "2022-02-08", "last_synced_at": "2026-09-02T07:36:19.338Z", "location_count": 25, "location_summary": "Phoenix, Arizona • Carlsbad, California • Los Angeles, California + 21 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Carlsbad", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03669588" }, { "nct_id": "NCT06528392", "title": "Efgartigimod for Stiff Person Syndrome (ESPS)", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Stiff-Person Syndrome" ], "interventions": [ { "name": "Efgartigimod", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "University of South Florida", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 10, "start_date": "2025-04-01", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2025-04-11", "last_synced_at": "2026-09-02T07:36:19.338Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06528392" } ] }